NCT05164458View on ClinicalTrials.gov

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

September 30, 2024

Conditions
Advanced Solid Tumors
Interventions
DRUG

IBI 308 injection

IBI308 IV 200mg Q3W Day1

DRUG

IBI 389 Injection

IBI 389 IV Q2\~Q3W Day 1

Trial Locations (1)

610000

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY